Clinical trials: Nonalcoholic Steatohepatitis
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
NASH (Non-alcoholic Steato-hepatitis)
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
- Trial name
- NCT01406704
- Testing
- Rosiglitazone, alpha-lipoic acid, Rosiglitazone/alpha-lipoic acid
- Volunteers
- 26 people
- Sponsor
- Seoul St. Mary's Hospital
Non-Alcoholic Fatty Liver Disease, Neurocognitive Disorders
Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease
This study investigates whether a structured lifestyle program can help improve thinking skills and liver health in adults with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT07294963
- Testing
- Structured Mediterranean Diet, Control / General Advice
- Where
- 2 sites in Pakistan
- Volunteers
- 45 people
- Sponsor
- Khyber Medical University Peshawar
Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
Lobeglitazone is highly selective peroxisome proliferator-activated receptor-gamma agonist that decreases insulin resistance in the periphery and liver resulting in increased insulin-dependent glucose disposal and decreased…
- Trial name
- NCT02285205
- Testing
- Oral administration of Lobeglitazone
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Yonsei University
Non-Alcoholic Fatty Liver Disease
High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder with high prevalence in patients suffering from chronic liver diseases [1].
- Trial name
- NCT05578404
- Testing
- Cholecalciferol
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
This study is a Phase 1, first-in-human single-dose escalation and multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic steatohepatitis.
- Trial name
- NCT05680233
- Testing
- OA-235i (4 mg), OA-235i (8 mg), OA-235i (16 mg)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Oasis Pharmaceuticals, LLC
Non Alcoholic Fatty Liver Disease
Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group
Investigation the Effects of Different Doses of SAMe in Subjects with Nonalcoholic Fatty Liver Disease and non-treated matched healthy volunteers as control group
- Trial name
- EXPO (NCT01754714)
- Testing
- SAMe 1000 mg, SAMe 1500 mg, SAMe 2000 mg
- Where
- 32 sites in France, Germany and 2 more
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Abbott
Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT04501406
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- University of Florida
Obesity, Nonalcoholic Fatty Liver Disease
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate potential metabolic effects of resveratrol in obese healthy men with non-alcoholic fatty liver disease.
- Trial name
- NCT01446276
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- University of Aarhus
Non-Alcoholic Fatty Liver Disease
Ultrasound Quantification of Liver Fat
The investigators plan a prospective study designed to evaluate the accuracy of a new ultrasound method for quantification of liver fat content.
- Trial name
- NCT04523584
- Testing
- Magnetic Resonance Imaging (MRI), Ultrasound Imaging
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Fatty Liver Disease, Chronic Hepatitis B
Impact of Fatty Liver on Hepatitis B Therapy
The primary goal of treating chronic hepatitis B(CHB) is to achieve maximal suppression of HBV replication, thereby reducing hepatocyte inflammation, necrosis, and liver fibrosis.
- Conditions
- Fatty Liver Disease, Chronic Hepatitis B, Antiviral Treatment
- Trial name
- AV-FLCHB (NCT06535048)
- Testing
- Entecavir；Tenofovir Disoproxil Fumarate (TDF)； Tenofovir alafenamide fumarate (TAF)；Interferons
- Volunteers
- 500 people
- Sponsor
- Tianjin Second People's Hospital
Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Non-alcoholic Fatty Liver Disease (NAFLD)
- Trial name
- NCT06947304
- Testing
- Miricorilant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Corcept Therapeutics
Non Alcoholic Fatty Liver Disease
Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH
Recent epidemiological studies in France showed a high prevalence of obesity (14.5%) and its strong increase in the last 20 years.
- Trial name
- NCT02820285
- Testing
- Evaluation of the staging of fibrosis liver, Determine the expression level of semaphorin, Determination of the composition of immunity cells
- Where
- France
- Volunteers
- 148 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
NAFLD( Non-alcoholic Fatty Liver Disease )
The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine
To investigate in subjects with non-alcoholic fatty liver disease the direct effects of a Chinese herb formula.
- Trial name
- NCT01677325
- Testing
- Chinese herb (YiQiSanJu)
- Volunteers
- 40 people
- Sponsor
- Fudan University
Nonalcoholic Fatty Liver Disease (NAFLD)
Anti-LPS Antibody Treatment for Pediatric NAFLD
The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver…
- Trial name
- NCT03042767
- Testing
- IMM-124E
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Miriam Vos, MD
NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Diabetes, Obesity, Metabolic Syndrome
- Trial name
- PROMETEO (NCT04371042)
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-alcoholic Fatty Liver Disease
Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and…
- Trial name
- NCT06707129
- Testing
- life-style
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing Municipal Administration of Hospitals
NAFLD
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.
- Trial name
- NCT03261739
- Testing
- RYI-018
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 84 people
- Sponsor
- Bird Rock Bio, Inc.
NASH, NAFLD
Assessment of Fatty Liver With Thermo-acoustic Device
The study will evaluate the accuracy of hepatic steatosis estimation by thermo-acoustic ultrasound with estimation by MRI-PDFF (Proton Density Fat Fraction) .
- Conditions
- NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04302051
- Testing
- Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Insulin Resistance, NAFLD
Reversal of Lipid-Induced Insulin Resistance
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have…
- Trial name
- NCT02193295
- Testing
- Caloric Restriction
- Where
- 2 sites in United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.